Keyword: Dupixent

Pfizer's abrocitinib, a JAK1-specific inhibitor, has met all co-primary and key secondary endpoints in a late-stage eczema study.

Dupixent has shown efficacy in multiple inflammations, but Regeneron CEO Len Schleifer wouldn't list COPD an indication it has "high confidence in."

Sanofi has been among those hardest hit by diabetes pressure, and now, competition is hurting the prized asset from its $11.6 billion Bioverativ buy.

AstraZeneca’s Fasenra is already pressuring GlaxoSmithKline's Nucala in severe eosinophilic asthma, and new data could help set up a showdown between the two in another indication.

Think the success of several megablockbusters such as AbbVie’s Humira means the anti-inflammation market is fully saturated? Think again.

Sanofi is working on a succession plan for CEO Olivier Brandicourt, who'll hit mandatory retirement age in 2021.

Some Big Pharma CEOs got big pay raises last year despite problems at their companies. Sanofi chief Olivier Brandicourt wasn't one of them.

Dupixent is now the first FDA-approved biologic for adolescents with eczema—and it's on the priority review track for adult sinusitis, too.

After a strong fourth quarter, Sanofi expects further growth in 2019.